1 July 2010
Breaking news:
Ashley J. Stevens, President of the AUTM, is attending Biofit 2010 ! |
 |
The Association of University Technology Managers (AUTM) is a global network of more than 3,500 technology transfer professionals who work in academic, research, government, legal and commercial settings. It is dedicated to promoting and supporting technology transfer through education, advocacy, networking and communication. |
| The President of the AUTM, M. Ashley J. Stevens, will make us the honor to participate to the BioFIT event. Thanks to his experience at the Boston University, at the Institute for Technology Entrepreneurship and Commercialization and his current position of President of the AUTM, his expertise will add a great value to BioFIT that will be appreciated by all its participants |
|
Breaking news:
The Biofit 2010 Conference schedule is now available |
| Conference Program Sponsor |
 |
9:00 - 10:30
| The place of OI in the biotechnology and healthcare sectors in 2010 |
The way partnerships work in the biotechnology and healthcare sectors recently went through a revolution called “open innovation.” Its core value is to combine complementary strengths and capabilities to mobilize the best global resources, experience and expertise.
The consequences of this new trend are important, as it renews every stage of the R&D to commercialization value chain and involves new ways of partnerships. What is the current position of the academia and the industry regarding this new way of leading the innovative process? |
11:00 - 12:30
Keynote speakers:
Steve Burrill, CEO, Burrill & Company ///
Ashley J. Stevens, President of the AUTM |
Lunch
2:00 - 3:30
| What is the role of “in-licensing” in current day academic technology transfer practice? |
| “In-licensing” was for a long time mainly associated to the world of industry, big pharmaceutical companies being known for leading this commercial practice. But time has changed and the different partners are actually evolving from their traditional position to seek new opportunities of development. The academia has followed this path, and is now more and more involved into “in-licensing.” What is at stake with this new trend? How optimizing this new role of the academia to create a win-win relationship with its partners? |
4:00 - 5:30
| Taking into account the human factor in collaborative projects: managing internal and external HR |
| Collaborating with a partner of a same profile is not easy as it requires like in any other human relation comprehensiveness and adaptation. But establishing a partnership with an actor from a very different work area is even more difficult. Open innovation imposes today to manage complex relationships of a new kind as the one between academics and their Tech Transfers Officers. We will discuss the concerns and reveal the best practices for making these new forms of partnerships a success. |
9:00 - 10:30
| Making the most of OI opportunities and avoiding their pitfalls |
| The growing importance of Open Innovation has introduced for the biotech, the pharmaceutical industries and the academia new opportunities as well as new risks. It requires from all the actors a new approach to investments, profit and IP-sharing and it completely renews the traditional models of partnerships. In order to encourage a future development of risk-limited and successful innovative projects, the industry and the academia will share their experience and give their advices to avoid the pitfalls. |
11:00 - 12:30
| The dos and don’ts of new partnering business models |
| Partnering business models have evolved to reach today a multitude of forms which present as many risks as potentials. Exploring the different existing models is the first step to learn about the good and bad practices in order to ensure a win-win relationship to all the partners. Experience and advice will be the keywords of this session. |
Lunch
2:00 - 3:30
| Creating the right financial and fiscal ecosystem for early stage biotechs |
| As the current economic climate is more and more encouraging venture capitalists to invest into risk-free enterprises, what are the options left for the early-stage biotech start-ups to finance their projects? How can these options benefit the start-up and the investor? Both the private and the public sectors offer opportunities which are useful to consider and which will be interesting to discuss. |
4:00 - 5:30
| How academia can capitalize on IP - to spin or not to spin? |
| Open innovation offers new opportunities of partnership and stimulates the actors to remodel their role. The academia, traditionally separated from the business world, is now encouraged to develop its commercial potential by capitalizing on its Intellectual Property. This can be done using various options already used sometimes like selling a patent or licensing. But the academic sphere is now encouraged to use an option even more revolutionary: starting a spin-off company. When does spinning makes sense, and when not? |
|
Who should attend to Biofit?
 R&D, licensing and business development managers
Technology transfer officers
Public and private laboratory directors
Investors
Public organizations supporting innovation
|
Biofit meetings are powered by partneringONE® is the leading conference partnering solution for the life sciences. Combining the industry’s most advanced collaboration software with best practice implementation, partneringONE ensures that Biofit will be a world-class partnering event.
|
Some organizations planning to attend
| ABBOTT BELGIUM |
| Ablynx |
| ALBEMARLE - EUROPE |
| ASCENION |
| AUTM |
| BD BIOSCIENCES |
| BERTIN PHARMA |
| BIO WIN |
| BIOCONNECTION B.V. |
| BIOPROTEIN TECHNOLOGIES |
| Burrill & Co |
| CANCER CAMPUS |
| CEA |
| CEIS INNOVATION 128 |
| CONECTUS ALSACE |
| DELPHI GENETICS |
| GEMAC |
| GHENT UNIVERSITY |
| Saint Antoine Research Institute - IRSSA |
| IP MANAGENMENT POLAND |
| IP Pragmatics |
| KATHOLIEKE UNIVERSITEIT LEUVEN |
| KPMG |
| KURMA BIOFUND |
| Les Laboratoires Servier |
| LICENTIA LTD. |
| Merck and Co |
| NORGINE |
| ROYAL HOLLOWAY UNIVERSITY |
| SANOFI PASTEUR |
| UNIVERSITY OF MANITOBA |
| TEVA PHARMACEUTICAL EUROPE BV |
| BORDEAUX UNIVERSITY |
| REIMS UNIVERSITY |
| UNIVERSITÉ LIBRE DE BRUXELLES |
| UniversitE de GenEve |
| PARIS 11 UNIVERSITY |
| UCB |
| UNIVERSITEIT ANTWERPEN |
| UNIVERSITEIT LEIDEN |
| UNIVERSITY TECHNION T3 |
| VRIJE UNIVERSITEIT BRUSSEL |
| WELLCOME TRUST |
| WELIENCE - UNIVERSITY OF BURGUNDY |
|
|
| Biofit 2010: the meeting place of prestigious speakers … |
| Meet here some of the speakers who already confirmed their participation to this event: |
Garold Breit, Executive Director, Technology Transfer Office (TTO) of the University of Manitoba, Canada
Biography »» | 
Steven Burill, Chief Executive Officer
of Burrill&Company, USA
Biography »» |
Nicholas Dunster, PhD, Senior Business Analyst, The Wellcome Trust, UK
Biography »» |
Manfred Horst, MD, PhD, MBA
Director, Licensing & External Research Europe, Merck & Co, Germany
Biography »» |
Alain Maiore, Managing Partner,
Kurma Biofund, France
Biography »» |
Laurent Miéville, Director of Unitec, Geneva University, Immediate Past President of ASTP, Switzerland
Biography »» |
Edwin Moses, CEO and Chairman
of the Board - Ablynx NV Germany
Biography »» |
Joseph Nathan, Director of New Ventures, Life Sciences & Medical, University Technion T3, Israel
Biography »» |
Rupert Osborn, PhD, CEO,
IP Pragmatics Ltd, UK
Biography »» |
Kari Paukkeri, Chief Executive Officer, Licentia Ltd., Finland
Biography »» |
Ashley J. Stevens, President of the AUTM, USA |
Patrice Talaga, Director Chemistry Outsourcing, UCB, Belgium
Biography »» |
 |
You are a recognized professional from the biotechnology area,
the pharmaceutical industry or the academia?
You are willing to share your experience to contribute to the development of technology transfer and collaborative projects in the life science sector?
Do not hesitate to join our team of speakers. |
|
Mature companies
